Liquid and low melting coatings for stents
Stents with coatings comprising a combination of a restenosis inhibitor comprising an HMG-CoA reductase inhibitor and a carrier. Also provided are methods of coating stents with a combination of an HMG-CoA reductase inhibitor and a carrier. A preferred example of a restenosis inhibitor is cerivastatin. The stent coatings have been shown to release restenosis inhibitors in their active forms.
1. A method of coating a stent comprising:
providing a stent;
providing a coating composition comprising an HMG-CoA reductase inhibitor in an amount of about 1 to 50 wt. %, and a polymeric biodegradable carrier component comprising a polymer selected from polycaprolactone, ethylene-vinyl acetate polymer, and a two-part silicone rubber;
expanding the stent to an increased diameter; and
applying the coating composition to the stent,
wherein the HMG-CoA reductase inhibitor is released from the stent at a rate of >20 μg/ml per day.
2. The method of claim 1 , wherein applying the coating composition comprises spraying or painting the coating composition onto the stent, or immersing the stent in the coating composition.
3. The method of claim 1 , wherein the HMG-CoA reductase inhibitor is selected from cerivastatin, atorvastatin, simvastatin, fluvastatin, lovastatin, and pravastatin.
4. The method of claim 1 , wherein the HMG-CoA reductase inhibitor comprises cerivastatin.
5. The method of claim 1 , wherein the coating composition further comprises one or more bioactive compounds selected from the group consisting of paclitaxel, paclitaxel analogs, actinomycin D, actinomycin D analogs, rapamycin, rapamycin analogs, and mixtures thereof.
6. A method of coating a stent comprising:
providing a stent;
providing a first coating composition comprising a first carrier and an HMG-CoA reductase inhibitor in an amount from about 1 to 50 wt. % of the first coating composition;
expanding the stent to an increased diameter;
applying the first coating composition to the stent;
drying the stent after the first coating composition is applied to the stent; and
applying a second coating composition comprising a polymeric biodegradable carrier to the dried stent.
7. The method of claim 6 , wherein providing the first coating composition comprises mixing the HMG-CoA reductase inhibitor, the first carrier, and a solvent under conditions such that the HMG-CoA reductase inhibitor does not chemically react to any substantial degree with the first carrier.
8. The method of claim 6 , wherein the first carrier comprises a nonpolymeric carrier.
9. The method of claim 8 , wherein the first carrier is a liquid at body temperature.
10. The method of claim 8 , wherein the first carrier is a solid at room temperature.
11. The method of claim 8 , wherein the nonpolymeric carrier is selected from the group consisting of Vitamin E, Vitamin E acetate, Vitamin E succinate, oleic acid, peanut oil and cottonseed oil.
12. The method of claim 6 , wherein the HMG-CoA reductase inhibitor is selected from the group consisting of cerivastatin, atorvastatin, simvastatin, fluvastatin, lovastatin, and pravastatin.
13. The method of claim 6 , wherein applying the first coating composition comprises spraying or painting the first coating composition onto the stent, or immersing the stent in the first coating composition.
14. The method of claim 6 , wherein providing the first coating composition comprises forming the first coating composition into a film, and applying the first coating comprises wrapping the film around the stent.
15. The method of claim 6 , wherein the polymeric biodegradable carrier comprises a polymer selected from polycaprolactone, ethylene-vinyl acetate polymer, and a two-part silicone rubber.
16. The method of claim 6 , wherein the second coating composition further comprises a substantially unreacted HMG-CoA reductase inhibitor.
17. The method of claim 6 , wherein the stent further comprises one or more bioactive compounds selected from the group consisting of paclitaxel, paclitaxel analogs, actinomycin D, actinomycin D analogs, rapamycin, rapamycin analogs, and mixtures thereof.
18. The method of claim 6 , wherein the HMG-CoA reductase inhibitor is released from the stent at a rate of >20 μg/ml per day.